United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

18 Aug 2017
Change (% chg)

$-0.05 (-2.70%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Mesoblast reports Q4 earnings per share $0.1278
Wednesday, 24 Aug 2016 06:41pm EDT 

Mesoblast Ltd : Mesoblast reports financial results and operational highlights for the three months and for the year ended 30 june 2016 .Q4 earnings per share $0.1278.  Full Article

Mesoblast provides update on global heart failure program
Monday, 13 Jun 2016 06:55pm EDT 

: Mesoblast provides update on global heart failure program . Mesoblast says regains worldwide rights to cardiovascular field for its cell therapy platform; no financial consideration to teva pharmaceuticals . Aims to complete phase 3 heart failure trial within eighteen months . To meet program's remaining funding requirements, has been offered an equity finance facility . U.S. FDA approved use of second navigational catheter system in phase 3 program for advanced heart failure . Independent committee recommends continuation of heart failure trial without modification after data review of first 175 patients . Second trial of mpc-150-im almost 60% recruited; results are expected in second half of 2017 .Has unencumbered rights to partner with a cardiovascular co with commitment to heart failure product commercialization.  Full Article

Mesoblast says co received $6.2 mln from Australian government for R&D
Thursday, 19 May 2016 07:55pm EDT 

Mesoblast Ltd : Mesoblast receives $6.2 million from Australian government for research and development activities . Anticipates that it will continue to receive Australian government funds for ongoing research and development activities undertaken during FY 2016 .  Full Article

Mesoblast Ltd announces pricing of public offering on Nasdaq
Friday, 13 Nov 2015 08:39am EST 

Mesoblast Ltd:Says initial public offering of 7.5 million ads priced at $8.00/ADS.  Full Article

Celgene and Mesoblast extend agreement
Thursday, 15 Oct 2015 07:50pm EDT 

Mesoblast:Says it has agreed with Celgene Corporation to extend for a period of six months Celgene's right of first refusal.Agreement with respect to Mesoblast's proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.  Full Article

BRIEF-Mesoblast Ltd files ‍​for $180 million American depositary shares representing ordinary shares

* Mesoblast Ltd - files ‍​for $180 million American depositary shares representing ordinary shares Source text: (http://bit.ly/2u50ziE) Further company coverage: